173 related articles for article (PubMed ID: 21947697)
1. Significance of pathologic response to preoperative therapy in pancreatic cancer.
Chun YS; Cooper HS; Cohen SJ; Konski A; Burtness B; Denlinger CS; Astsaturov I; Hall MJ; Hoffman JP
Ann Surg Oncol; 2011 Dec; 18(13):3601-7. PubMed ID: 21947697
[TBL] [Abstract][Full Text] [Related]
2. Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.
Le Scodan R; Mornex F; Partensky C; Mercier C; Valette PJ; Ychou M; Roy P; Scoazec JY
Am J Clin Oncol; 2008 Dec; 31(6):545-52. PubMed ID: 19060585
[TBL] [Abstract][Full Text] [Related]
3. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
[TBL] [Abstract][Full Text] [Related]
4. Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients.
Lorenzen S; Blank S; Lordick F; Siewert JR; Ott K
Ann Surg Oncol; 2012 Jul; 19(7):2119-27. PubMed ID: 22395980
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response.
Turrini O; Ychou M; Moureau-Zabotto L; Rouanet P; Giovannini M; Moutardier V; Azria D; Delpero JR; Viret F
Eur J Surg Oncol; 2010 Oct; 36(10):987-92. PubMed ID: 20828979
[TBL] [Abstract][Full Text] [Related]
6. Preoperative CA 19-9 level is an important prognostic factor in patients with pancreatic adenocarcinoma treated with surgical resection and adjuvant concurrent chemoradiotherapy.
Hallemeier CL; Botros M; Corsini MM; Haddock MG; Gunderson LL; Miller RC
Am J Clin Oncol; 2011 Dec; 34(6):567-72. PubMed ID: 21150564
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors.
Cleary SP; Gryfe R; Guindi M; Greig P; Smith L; Mackenzie R; Strasberg S; Hanna S; Taylor B; Langer B; Gallinger S
J Am Coll Surg; 2004 May; 198(5):722-31. PubMed ID: 15110805
[TBL] [Abstract][Full Text] [Related]
8. Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma.
Brown KM; Siripurapu V; Davidson M; Cohen SJ; Konski A; Watson JC; Li T; Ciocca V; Cooper H; Hoffman JP
Am J Surg; 2008 Mar; 195(3):318-21. PubMed ID: 18308038
[TBL] [Abstract][Full Text] [Related]
9. Resection status, age and nodal involvement determine survival among patients receiving adjuvant chemoradiotherapy in pancreatic adenocarcinoma.
Moghanaki D; Mick R; Furth EE; Sohal D; Salmon PM; Behbahani A; Morgans AK; Miller SM; Giantonio BJ; Whittington RW; Haller DG; Rosato EF; Plastaras JP
JOP; 2011 Sep; 12(5):438-44. PubMed ID: 21904068
[TBL] [Abstract][Full Text] [Related]
10. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
[TBL] [Abstract][Full Text] [Related]
11. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
12. Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy?
Kuo LJ; Liu MC; Jian JJ; Horng CF; Cheng TI; Chen CM; Fang WT; Chung YL
Ann Surg Oncol; 2007 Oct; 14(10):2766-72. PubMed ID: 17551794
[TBL] [Abstract][Full Text] [Related]
13. A single institutional experience with preoperative chemoradiotherapy for stage I-III pancreatic adenocarcinoma.
Hoffman JP; Weese JL; Solin LJ; Agarwal P; Engstrom P; Scher R; Paul AR; Litwin S; Watts P; Eisenberg BL
Am Surg; 1993 Nov; 59(11):772-80; discussion 780-1. PubMed ID: 7902052
[TBL] [Abstract][Full Text] [Related]
14. Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer.
Biankin AV; Kench JG; Colvin EK; Segara D; Scarlett CJ; Nguyen NQ; Chang DK; Morey AL; Lee CS; Pinese M; Kuo SC; Susanto JM; Cosman PH; Lindeman GJ; Visvader JE; Nguyen TV; Merrett ND; Warusavitarne J; Musgrove EA; Henshall SM; Sutherland RL;
Gastroenterology; 2009 Aug; 137(2):558-68, 568.e1-11. PubMed ID: 19376121
[TBL] [Abstract][Full Text] [Related]
15. Downstaging without complete pathologic response after neoadjuvant treatment improves cancer outcomes for cIII but not cII rectal cancers.
de Campos-Lobato LF; Stocchi L; da Luz Moreira A; Kalady MF; Geisler D; Dietz D; Lavery IC; Remzi FH; Fazio VW
Ann Surg Oncol; 2010 Jul; 17(7):1758-66. PubMed ID: 20131015
[TBL] [Abstract][Full Text] [Related]
16. Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients.
Bonnen M; Crane C; Vauthey JN; Skibber J; Delclos ME; Rodriguez-Bigas M; Hoff PM; Lin E; Eng C; Wong A; Janjan NA; Feig BW
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1098-105. PubMed ID: 15519780
[TBL] [Abstract][Full Text] [Related]
17. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer?
Mansour JC; Tang L; Shah M; Bentrem D; Klimstra DS; Gonen M; Kelsen DP; Brennan MF; Coit DG
Ann Surg Oncol; 2007 Dec; 14(12):3412-8. PubMed ID: 17909917
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005).
Corsini MM; Miller RC; Haddock MG; Donohue JH; Farnell MB; Nagorney DM; Jatoi A; McWilliams RR; Kim GP; Bhatia S; Iott MJ; Gunderson LL
J Clin Oncol; 2008 Jul; 26(21):3511-6. PubMed ID: 18640932
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?
Schnelldorfer T; Ware AL; Sarr MG; Smyrk TC; Zhang L; Qin R; Gullerud RE; Donohue JH; Nagorney DM; Farnell MB
Ann Surg; 2008 Mar; 247(3):456-62. PubMed ID: 18376190
[TBL] [Abstract][Full Text] [Related]
20. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
